History of Japan Clinical Oncology Group (JCOG) Lung Cancer Study Group-Reference-Cited by-同舟云学术

History of Japan Clinical Oncology Group (JCOG) Lung Cancer Study Group

Published:2020-03-02 Issue:5 Volume:50 Page:502-511
ISSN:1465-3621
Container-title:Japanese Journal of Clinical Oncology
language:en
Short-container-title:

Author:

Horinouchi Hidehito¹^ORCID,Ohe Yuichiro¹

Affiliation:

1. Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan

Abstract

Abstract The Japan Clinical Oncology Group Lung Cancer Study Group has been carrying out clinical studies, exploring new strategies of treatment, supportive therapies (antiemetics, etc.), etc., for a variety of cancers, including not only small cell lung cancer and non-small cell lung cancer but also rare chest tumours (represented by thymoma) and cancer-associated conditions (cancerous pericarditis, cancerous pleuritis, etc.). In this review, an overview of all studies conducted from 1985 to 2019 is provided.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Link

http://academic.oup.com/jjco/article-pdf/50/5/502/33180279/hyaa031.pdf

Reference48 articles.

1. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer;Fukuoka;J Natl Cancer Inst,1991

2. Concurrent cisplatin-etoposide chemotherapy plus thoracic radiotherapy for limited-stage small cell lung cancer. Japanese lung cancer chemotherapy Group in Japanese Clinical Oncology Group;Ariyoshi;Jpn J Clin Oncol,1994

3. A study of dose escalation of teniposide (VM-26) plus cisplatin (CDDP) with recombinant human granulocyte colony-stimulating factor (rh G-CSF) in patients with advanced small cell lung cancer;Eguchi;Eur J Cancer,1994

4. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan clinical oncology group study 9104;Takada;J Clin Oncol,2002

5. Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan clinical oncology group;Furuse;J Clin Oncol,1998

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MALAT-1 Expression Correlates with Prognosis in Non-Small-Cell Lung Carcinoma: A Systematic Review and Meta-analysis;Disease Markers;2021-11-23